Comparison 3.
DAA on or on the way to the market versus placebo/no intervention
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Without sustained virological response | 61 | 7115 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 2 Without sustained virological response ‐ bias risk | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 2.1 Trials at high risk of bias | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 2.2 Trials at low risk of bias | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 3 Without sustained virological response ‐ according to type of DAA | 61 | 7115 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 3.1 ABT‐072 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.2 ACH‐2684 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.3 Alisporivir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.4 ALS‐2200 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.5 Asunaprevir | 4 | 285 | Risk Ratio (M‐H, Random, 95% CI) | 0.49 [0.29, 0.85] |
| 3.6 Balapiravir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.7 Beclabuvir | 2 | 39 | Risk Ratio (M‐H, Random, 95% CI) | 0.78 [0.43, 1.40] |
| 3.8 BILB‐1941 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.9 BIT‐225 | 1 | 23 | Risk Ratio (M‐H, Random, 95% CI) | 0.27 [0.03, 2.51] |
| 3.10 Boceprevir | 1 | 229 | Risk Ratio (M‐H, Random, 95% CI) | 0.42 [0.29, 0.61] |
| 3.11 Ciluprevir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.12 Daclatasvir | 7 | 619 | Risk Ratio (M‐H, Random, 95% CI) | 0.60 [0.50, 0.73] |
| 3.13 Danoprevir | 5 | 642 | Risk Ratio (M‐H, Random, 95% CI) | 0.38 [0.28, 0.51] |
| 3.14 Dasabuvir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.15 Deleobuvir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.16 Faldaprevir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.17 Filibuvir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.18 Grazoprevir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.19 GS‐6620 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.20 GS‐9256 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.21 GS‐9451 | 1 | 329 | Risk Ratio (M‐H, Random, 95% CI) | 0.42 [0.26, 0.67] |
| 3.22 GS‐9669 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.23 GS‐9851 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.24 GS‐9857 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.25 GSK2336805 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.26 GSK2878175 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.27 IDX‐184 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.28 INX‐08189 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.29 Ledispasvir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.30 Mericitabine | 4 | 725 | Risk Ratio (M‐H, Random, 95% CI) | 0.78 [0.49, 1.27] |
| 3.31 Narlaprevir | 2 | 40 | Risk Ratio (M‐H, Random, 95% CI) | 0.69 [0.43, 1.09] |
| 3.32 Nesbuvir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.33 Odalasavir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.34 Ombitasvir | 1 | 37 | Risk Ratio (M‐H, Random, 95% CI) | 0.64 [0.39, 1.07] |
| 3.35 Paritaprevir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.36 PHX1766 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.37 PPI‐461 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.38 PSI‐352938 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.39 Samatasvir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.40 Setrobuvir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.41 Simeprevir | 19 | 2898 | Risk Ratio (M‐H, Random, 95% CI) | 0.39 [0.33, 0.46] |
| 3.42 Sofosbuvir | 3 | 181 | Risk Ratio (M‐H, Random, 95% CI) | 0.34 [0.20, 0.58] |
| 3.43 Sovaprevir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.44 Tegobuvir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.45 Telaprevir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.46 Valopicitabine | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.47 Vaniprevir | 9 | 333 | Risk Ratio (M‐H, Random, 95% CI) | 0.33 [0.25, 0.43] |
| 3.48 VCH‐759 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.49 VCH‐916 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.50 Velpatasvir | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.51 VX‐222 | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 3.52 Mixed | 2 | 735 | Risk Ratio (M‐H, Random, 95% CI) | 0.06 [0.00, 7.05] |
| 4 Without sustained virological response ‐ according to group of DAA | 61 | 7115 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 4.1 Cyclophilin | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 4.2 NS3/NS4A inhibitors | 41 | 4756 | Risk Ratio (M‐H, Random, 95% CI) | 0.41 [0.36, 0.46] |
| 4.3 NS5B inhibitors (NPI) | 7 | 906 | Risk Ratio (M‐H, Random, 95% CI) | 0.57 [0.36, 0.90] |
| 4.4 NS5B inhibitors (NNPI) | 2 | 39 | Risk Ratio (M‐H, Random, 95% CI) | 0.78 [0.43, 1.40] |
| 4.5 NS5A inhibitors | 9 | 686 | Risk Ratio (M‐H, Random, 95% CI) | 0.59 [0.49, 0.69] |
| 4.6 VPU‐ion channel inhibitors | 1 | 23 | Risk Ratio (M‐H, Random, 95% CI) | 0.27 [0.03, 2.51] |
| 4.7 Mixed | 1 | 705 | Risk Ratio (M‐H, Random, 95% CI) | 0.01 [0.00, 0.02] |
| 5 Without sustained virological response ‐ according to HIV‐infection | 61 | 7115 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 5.1 With HIV‐infection | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 5.2 Without HIV‐infection | 58 | 6726 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 5.3 Mixed (with and without HIV‐infection) | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 5.4 Unclear | 3 | 389 | Risk Ratio (M‐H, Random, 95% CI) | 0.50 [0.35, 0.72] |
| 6 Without sustained virological response ‐ according to comorbidity | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 6.1 With comorbidity | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 6.2 Without comorbidity | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 6.3 Unclear | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 7 Without sustained virological response ‐ according to viral genotype | 58 | 7098 | Risk Ratio (M‐H, Random, 95% CI) | 0.43 [0.36, 0.51] |
| 7.1 Genotype 1 | 54 | 5984 | Risk Ratio (M‐H, Random, 95% CI) | 0.43 [0.37, 0.50] |
| 7.2 Genotype 2 | 3 | 185 | Risk Ratio (M‐H, Random, 95% CI) | 0.14 [0.01, 3.21] |
| 7.3 Genotype 3 | 2 | 80 | Risk Ratio (M‐H, Random, 95% CI) | 0.79 [0.43, 1.43] |
| 7.4 Genotype 4 | 5 | 226 | Risk Ratio (M‐H, Random, 95% CI) | 0.10 [0.02, 0.68] |
| 7.5 Genotype 6 | 1 | 49 | Risk Ratio (M‐H, Random, 95% CI) | 0.01 [0.00, 0.20] |
| 7.6 Mixed | 2 | 574 | Risk Ratio (M‐H, Random, 95% CI) | 0.92 [0.52, 1.62] |
| 8 Without sustained virological response ‐ according to human genotype (IL28b) | 58 | 6745 | Risk Ratio (M‐H, Random, 95% CI) | 0.46 [0.40, 0.54] |
| 8.1 IL28b (CC) | 25 | 1444 | Risk Ratio (M‐H, Random, 95% CI) | 0.42 [0.29, 0.61] |
| 8.2 IL28B (CT) | 10 | 1304 | Risk Ratio (M‐H, Random, 95% CI) | 0.52 [0.42, 0.66] |
| 8.3 IL28B (TT) | 10 | 359 | Risk Ratio (M‐H, Random, 95% CI) | 0.54 [0.44, 0.67] |
| 8.4 IL28B (CT + TT) | 14 | 1798 | Risk Ratio (M‐H, Random, 95% CI) | 0.37 [0.23, 0.57] |
| 8.5 Unclear | 7 | 147 | Risk Ratio (M‐H, Random, 95% CI) | 0.47 [0.33, 0.68] |
| 8.6 Mixed | 26 | 1693 | Risk Ratio (M‐H, Random, 95% CI) | 0.51 [0.40, 0.63] |
| 9 Without sustained virological response ‐ according to Asian‐region | 61 | 7115 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 9.1 From Asian region | 10 | 1128 | Risk Ratio (M‐H, Random, 95% CI) | 0.34 [0.28, 0.42] |
| 9.2 Not from Asian region | 42 | 4910 | Risk Ratio (M‐H, Random, 95% CI) | 0.51 [0.43, 0.60] |
| 9.3 Mixed | 7 | 1010 | Risk Ratio (M‐H, Random, 95% CI) | 0.19 [0.03, 1.17] |
| 9.4 Unclear | 2 | 67 | Risk Ratio (M‐H, Random, 95% CI) | 0.53 [0.35, 0.79] |
| 10 Without sustained virological response ‐ according to specific ethnicities | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 10.1 White | 2 | 412 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.15, 0.38] |
| 10.2 Black | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 10.3 Hispanic | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 10.4 Mixed | 48 | 5384 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.23 [0.20, 0.27] |
| 10.5 Unclear | 9 | 862 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.28 [0.20, 0.39] |
| 10.6 Asian | 2 | 457 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.38 [0.23, 0.63] |
| 11 Without sustained virological response ‐ according to reaching planned sample size | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 11.1 Trials reaching planned sample size | 13 | 3071 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.21 [0.18, 0.25] |
| 11.2 Trials not reaching planned sample size | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 11.3 Unclear | 48 | 4044 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.28 [0.23, 0.33] |
| 12 Without sustained virological response ‐ according to prior treatment | 61 | 7115 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 12.1 Treatment‐naive | 44 | 4777 | Risk Ratio (M‐H, Random, 95% CI) | 0.48 [0.41, 0.56] |
| 12.2 Treatment‐experienced | 13 | 1274 | Risk Ratio (M‐H, Random, 95% CI) | 0.50 [0.36, 0.69] |
| 12.3 Mixed | 4 | 1064 | Risk Ratio (M‐H, Random, 95% CI) | 0.15 [0.02, 0.96] |
| 12.4 Unclear | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 13 Without sustained virological response ‐ according to interferon | 61 | 7115 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 13.1 Trials where both groups received interferon | 57 | 6229 | Risk Ratio (M‐H, Random, 95% CI) | 0.47 [0.41, 0.54] |
| 13.2 Trials where neither group received interferon | 2 | 735 | Risk Ratio (M‐H, Random, 95% CI) | 0.06 [0.00, 7.05] |
| 13.3 Trials where only the experimental group received interferon | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 13.4 Trials where only the control group received interferon | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 13.5 Mixed | 2 | 151 | Risk Ratio (M‐H, Random, 95% CI) | 0.58 [0.15, 2.30] |
| 14 Without sustained virological response ‐ according to ribavirin | 61 | 7115 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 14.1 Trials where both groups received ribavirin | 60 | 6410 | Risk Ratio (M‐H, Random, 95% CI) | 0.47 [0.41, 0.55] |
| 14.2 Trials where neither group received ribavirin | 1 | 705 | Risk Ratio (M‐H, Random, 95% CI) | 0.01 [0.00, 0.02] |
| 14.3 Trials where only the experimental group received ribavirin | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 14.4 Trials where only the control group received ribavirin | 0 | 0 | Risk Ratio (M‐H, Random, 95% CI) | 0.0 [0.0, 0.0] |
| 15 Without sustained virological response ‐ according to chronic kidney disease | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 15.1 With chronic kidney disease | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 15.2 Without chronic kidney disease | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 15.3 Unclear | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 16 Without sustained virological response ‐ according to cryoglobulinaemia | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 16.1 With cryoglobulinaemia | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 16.2 Without cryoglobulinaemia | 0 | 0 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |
| 16.3 Unclear | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 17 Without sustained virological response ‐ according to DAA group as co‐intervention | 61 | 7115 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.24 [0.22, 0.27] |
| 17.1 Trials where DAA were used as co‐intervention | 3 | 480 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.42 [0.27, 0.66] |
| 17.2 Trials where DAA were not a co‐intervention | 58 | 6635 | Odds Ratio (M‐H, Fixed, 95% CI) | 0.23 [0.21, 0.26] |
| 18 Without sustained virological response ‐ 'Best‐worst case' scenario | 61 | 7294 | Risk Ratio (M‐H, Random, 95% CI) | 0.41 [0.34, 0.49] |
| 19 Without sustained virological response ‐ 'Worst‐best case' scenario | 61 | 7294 | Risk Ratio (M‐H, Random, 95% CI) | 0.51 [0.43, 0.60] |
| 20 Without sustained virological response ‐ according to median dose | 61 | 7115 | Risk Ratio (M‐H, Random, 95% CI) | 0.44 [0.37, 0.52] |
| 20.1 Over or equal to median dose | 34 | 4154 | Risk Ratio (M‐H, Random, 95% CI) | 0.41 [0.32, 0.53] |
| 20.2 Under median dose | 23 | 2086 | Risk Ratio (M‐H, Random, 95% CI) | 0.46 [0.39, 0.55] |
| 20.3 Not available | 4 | 875 | Risk Ratio (M‐H, Random, 95% CI) | 0.62 [0.26, 1.47] |